Determination of enzyme (angiotensin convertase) inhibitors based on enzymatic reaction followed by HPLC

被引:26
作者
Anzenbacherová, E
Anzenbacher, P
Macek, K
Kvetina, J
机构
[1] Acad Sci Czech Republ, PRO MED CS Praha AS, Joint Res Ctr, Inst Expt Biopharmaceut, Hradec Kralove 50002, Czech Republic
[2] Fac Hosp, Dept Internal Med, Hradec Kralove 50002, Czech Republic
关键词
angiotensin converting enzyme; enzyme assay; reversed phase-HPLC; angiotensin I convertase enzyme-inhibitors; enalapril; lisinopril;
D O I
10.1016/S0731-7085(00)00576-8
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
For determination of levels of plasmatic inhibitor of ACE (angiotensin convertase) a simple method was used based on a combination of enzymatic reaction followed by an HPLC determination of its product. The inhibitor (e.g. enalaprilat) was at first separated from the biological material by deproteination (methanol). Then, an aliquot of the sample was added to the reaction mixture containing a commercial ACE enzyme, its specific substrate FAPGG (N-(3-[2-furyl]acryloyl)-Phe-Gly-Gly and buffer (Tris-HCl, pH 7.5). Degree of inhibition of the conversion of this substrate to FAP (desGlyGlyFAPGG) by the inhibitor present in the sample is related to its amount by a simple dose-response relationship. The amount of the FAP was determined by an HPLC on a RP-18 column with an acetonitril-nonylamine buffer (pH 2.4, adjusted with phosphoric acid) as a mobile phase with detection at 305 nm. Alternatively, the activity of the endogenous ACE present in the plasma was measured. The substrate FAPGG was added to the plasmatic sample containing both the inhibitor and endogenous ACE las the sample was not deproteinized in this case) and the reaction product was determined as above. Inhibitor concentration has been obtained from a dose-response curve expressing the interaction with inhibitor with an ACE enzyme. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:1151 / 1156
页数:6
相关论文
共 10 条
  • [1] RECENT ADVANCES IN KNOWLEDGE OF THE STRUCTURE AND FUNCTION OF THE ANGIOTENSIN-I CONVERTING-ENZYME
    CORVOL, P
    MICHAUD, A
    SOUBRIER, F
    WILLIAMS, TA
    [J]. JOURNAL OF HYPERTENSION, 1995, 13 : S3 - S10
  • [2] CORVOL P, 1995, METHOD ENZYMOL, V248, P283
  • [3] EDEKI T, 1994, INT J CLIN PHARM TH, V32, P142
  • [4] HICHENS M, 1981, Ligand Quarterly, V4, P43
  • [5] UNDERSTANDING THE DOSE-EFFECT RELATIONSHIP - CLINICAL-APPLICATION OF PHARMACOKINETIC-PHARMACODYNAMIC MODELS
    HOLFORD, NHG
    SHEINER, LB
    [J]. CLINICAL PHARMACOKINETICS, 1981, 6 (06) : 429 - 453
  • [6] CONTINUOUS SPECTROPHOTOMETRIC ASSAY FOR ANGIOTENSIN CONVERTING ENZYME
    HOLMQUIST, B
    BUNNING, P
    RIORDAN, JF
    [J]. ANALYTICAL BIOCHEMISTRY, 1979, 95 (02) : 540 - 548
  • [7] KOSTIS JB, 1998, AM HEART J DEC, P1580
  • [8] Bioequivalence study of two enalapril maleate tablet formulations in healthy male volunteers - Pharmacokinetic versus pharmacodynamic approach
    Ribeiro, W
    Muscara, MN
    Martins, AR
    Moreno, H
    Mendes, GB
    deNucci, G
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 50 (05) : 399 - 405
  • [9] SWANSON BN, 1985, ANAL BIOCHEM, V148, P401, DOI 10.1016/0003-2697(85)90245-3
  • [10] TOCCO DJ, 1982, DRUG METAB DISPOS, V10, P15